Onyx Seeks Suitors After Rejecting $120-a-Share Amgen Bid

Onyx Pharmaceuticals Inc., the maker of the cancer drug Nexavar, said it is in contact with other possible acquirers after rejecting an unsolicited $120-a-share cash takeover bid from Amgen Inc. Onyx shares surged.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.